Oncologists discuss long-term ibrutinib use, cardiovascular risks with BTK inhibitors, and emerging fixed-duration acalabrutinib-venetoclax therapy in CLL.
Related to this article
The phase 3 GIMEMA ALL2820 trial found improved event-free survival and molecular responses with frontline ponatinib plus blinatumomab vs imatinib and chemotherapy.
The FDA grants orphan drug designation to TRX-E-002-1, an investigational small-molecule benzopyran, for the treatment of acute myeloid leukemia (AML).
Advertisement
Advertisement
Trending on Targeted Onc
1
Dr Chauhan on DLL3 Expression and Obrixtamig Outcomes in DAREON-7
2
FDA Approves OncoMate MSI Dx For Pembrolizumab in MSI-H Tumors
3
Phase 3 Results Point to a Path Forward for Cancer Vaccines
4
FDA Approves Durvalumab-EV Combo, Expanding MIBC Treatment Options
5